Symrise AG

Symrise AG’s stock surges on regulatory relief and buy upgrades, with Goldman Sachs targeting €83 amid growing institutional confidence and strong margin prospects.

Symrise AG boosts shares with portfolio shift and first buy‑back, signalling stronger margins and shareholder value ahead of a robust recovery.

Discover why MFS Series Trust X’s 5% stake in Symrise AG at a market low signals confidence—read how this move could boost liquidity, influence governance, and shape future returns.

Symrise AG faces new regulatory scrutiny and insider activity while investing in Cellibre’s clean‑beauty biotech—balancing short‑term risk with long‑term sustainable growth.

Symrise AG has adjusted its growth outlook for 2025 due to weakening consumer demand, but remains optimistic about achieving 3-5% organic revenue growth.

Symrise AG has adjusted its 2025 growth expectations to 3-5% due to market changes, but its stock performance remains stable and the company is making strategic moves to strengthen its position in the chemicals industry.

Symrise AG, a German chemical manufacturer, is experiencing a challenging period due to internal performance issues and industry pressures, leading to a decline in its stock value and market capitalization.

Symrise AG’s stock was downgraded by Jefferies due to concerns over demand, leading to a reduction in its stock price target and a subdued start to the DAX index.

Symrise AG, a German chemical manufacturer, is navigating market challenges through strategic reorientation and portfolio adjustments, positioning itself for sustained growth and success in the global chemical industry.